Last Updated: May 10, 2026

List of Excipients in Branded Drug CVS IBUPROFEN


✉ Email this page to a colleague

« Back to Dashboard


Excipient Strategy and Commercial Opportunities for CVS Ibuprofen

Last updated: March 1, 2026

What is the Excipient Profile for CVS Ibuprofen?

CVS Pharmacy’s ibuprofen formulations typically include excipients to ensure stability, bioavailability, and user acceptability. Common excipients in over-the-counter (OTC) ibuprofen tablets include:

  • Microcrystalline cellulose (Filler and disintegrant)
  • Aluminum hydroxide (Antacid action, sometimes in combo products)
  • Stearic acid (Lubricant)
  • Corn starch (Disintegrant)
  • Povidone (Binder)
  • Magnesium stearate (Lubricant)

CVS’s specific formulation details are proprietary; however, these are standard ingredients aligned with OTC ibuprofen products. The excipient selection aims for quick dissolution, minimized gastrointestinal irritation, and reproducible dosing.

How Does the Excipient Strategy Influence Formulation and Differentiation?

Selective excipient use affects:

  • Shelf stability: Use of antioxidants like ascorbyl palmitate prolongs shelf life.
  • Bioavailability: Formulators optimize disintegration and dissolution to ensure rapid pain relief.
  • Patient tolerability: Inclusion of minimal irritants and tolerable excipients reduces adverse effects.
  • Manufacturing efficiency: Use of excipients compatible with high-speed production lines reduces costs.

CVS’s OTC positioning emphasizes formulations with familiar excipients, ensuring consumer confidence. The choice of excipients aligns with regulatory requirements and quality standards relevant to OTC drugs.

Commercial Opportunities in Excipient Innovation

  1. Enhanced Bioavailability Formulations
    Development of pre-dissolved systems or lipid-based formulations can improve absorption, especially in populations with impaired gastrointestinal function.

  2. Taste Masking and Formulation Improvements
    Incorporation of flavoring agents with excipients that mask bitterness expands consumer appeal, especially for pediatric or sensitive consumers.

  3. Reducing Excipient Load
    Low-excipient or excipient-free formulations cater to consumers seeking "clean-label" OTC products, presenting a niche market.

  4. Sustainable and Natural Excipients
    Use of plant-based or biodegradable excipients appeals to environmentally conscious consumers and aligns with emerging regulations.

  5. Combination Products
    Integrating excipients that support multi-ingredient formulations (e.g., ibuprofen with paracetamol or antihistamines) increases convenience and market share.

Market Trends and Regulatory Environment

  • The OTC analgesic market is projected to grow at a CAGR of 4.8% (2021–2028) [1].
  • Regulatory agencies emphasize excipient safety; updates on permissible levels and novel excipients influence formulation choices.
  • Consumer preference shifts toward minimal and transparent ingredient lists favor formulations with fewer excipients or naturally derived ingredients.

Strategic Considerations

  • Innovation pipeline: Focus on modifications that improve absorption and tolerability, using excipients compatible with existing manufacturing infrastructure.
  • Regulatory pathways: Leverage existing OTC monographs, but consider novel excipients approval routes if innovating.
  • Partnerships: Collaborate with excipient suppliers investing in sustainable and functional ingredients.

Conclusion

CVS’s ibuprofen formulations rely on standard excipients prioritizing safety, efficacy, and manufacturability. Opportunities exist in developing bioavailability-enhanced, taste-masked, low excipient, or sustainable formulations. Regulatory trends and consumer preferences favor transparent, minimally invasive ingredient profiles, opening pathways for innovative excipient strategies.

Key Takeaways

  • Established excipient use in CVS ibuprofen supports safety and functionality.
  • Innovation opportunities include bioavailability enhancements, natural excipients, and reduced excipient load.
  • Market growth and regulatory focus on excipient safety create opportunities for differentiated formulations.
  • Consumer demand for transparency and sustainability influences excipient selection.
  • Strategic partnerships with excipient providers can enhance development of novel formulations.

FAQs

1. What excipients are commonly used in OTC ibuprofen formulations?
Microcrystalline cellulose, stearic acid (magnesium stearate), corn starch, povidone, and aluminum hydroxide are typical.

2. How can excipient innovation impact CVS ibuprofen products?
Innovations can improve absorption, reduce irritation, enhance taste, and meet consumer preferences for natural or low-excipient products.

3. Are there regulations governing excipient use in OTC drugs?
Yes, agencies like the FDA regulate excipient safety, permissible levels, and require Good Manufacturing Practices (GMP).

4. What role does consumer preference play in excipient selection?
Consumers prefer transparent, natural, and minimal ingredient profiles, influencing formulation strategies.

5. How does sustainability influence excipient choices?
Sustainable, biodegradable excipients align with environmental standards and appeal to eco-conscious consumers, creating market differentiation.


References

[1] MarketWatch. (2022). OTC analgesics market analysis.

[2] U.S. Food and Drug Administration. (2021). Guidance for Industry: Nonclinical Safety Testing of Cosmetic Ingredients.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.